N Engl J Med January 2024 PMID 38197816

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.

Julian D Gillmore, Daniel P Judge, Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, Simon Gibbs, Martha Grogan, Mazen Hanna, James Hoffman, Ahmad Masri, Mathew S Maurer, Jose Nativi-Nicolau, Laura Obici, Steen Hvitfeldt Poulsen, Frank Rockhold

Full text PDF Download social card

Mentions

215

Peak: 121 in Jan 2024

across 5 sources since Aug 2023

Extended reach

2,580,942

potential audience

Total likes

471

Video views

Mentions per month

Aug 2023 – Apr 2025

Where it's discussed

X / Twitter142 posts
News63 articles
Blogs6 articles
YouTube2 videos
Facebook2 posts

AI synopsis

What people are saying

Several discussions highlight the efficacy of acoramidis, with phrases like 'exciting news' and 'triumphs in treating ATTR amyloidosis' emphasizing the positive tone around its approval. Comments about expanding treatment options and references to competition with existing therapies, like tafamidis, illustrate a deep engagement with the topic. The choice of enthusiastic language and an optimistic context contribute to a strong sense of community support for the potential advancements in treating transthyretin amyloid cardiomyopathy.

AgreementModerate agreement

The majority of discussions showcase support for the findings related to acoramidis, indicating a general consensus on its effectiveness.

InterestHigh interest

Many participants express high levels of curiosity about acoramidis and its implications for treatment, reflecting significant relevance.

EngagementModerate engagement

While some posts delve into technical details about the trial and methodology, others offer general excitement about the drug's approval.

ImpactHigh impact

The conversations reveal a strong belief that the findings will have a significant effect on treatment options for the condition.

Abstract in brief

Transthyretin amyloid cardiomyopathy involves the buildup of misfolded proteins in the heart, and acoramidis is a medication designed to stabilize these proteins, showing over 90% effectiveness in laboratory tests.
In a phase 3 trial, 632 patients were randomly assigned to receive either acoramidis or a placebo for 30 months, evaluating outcomes like death rates, hospitalizations, and specific health indicators.
The results demonstrated that acoramidis significantly outperformed the placebo in multiple health measures, with a high win ratio favoring acoramidis, while the frequency of side effects was similar in both groups.

Read the full abstract

All mentions

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy

Medscape · Mar 27, 2024 47 views

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy

This video discusses a step towards a cure for transthyretin amyloid cardiomyopathy with acoramidis, which stabilizes misfolded proteins in the heart. In a phase 3 trial, acoramidis significantly improved health…

SciSnag · Jan 12, 2024 32 views

Cornerstone Medical Education

@Cornerstone_CME · X

RT @MasriAhmadMD: Recap on ATTRibute-CM (acoramidis vs placebo in ATTR-CM) and selected subsequent analyses https://t.co/z86XZVrs01 #card…

Apr 15, 2025 · 1 share · 144 followers View post →

Ahmad Masri

@MasriAhmadMD · X

Recap on ATTRibute-CM (acoramidis vs placebo in ATTR-CM) and selected subsequent analyses https://t.co/z86XZVrs01 #cardiotwitter

Apr 14, 2025 · 5 likes · 1 share · 8,931 followers View post →

Takeru Nabeta

@nebetake · X

ちなみにATTRibute-CM試験はNEJMに発表されていますが、primary endpointがいくつかの項目からなるHierarchical endpointだったこともあり、今回の解析が行われています。 https://t.co/p9VLolBdIm

Mar 21, 2025 · 5 likes · 2,183 followers View post →

Ko Harada

@Ko__Harada · X

1. https://t.co/cPgNPcAHw4 2. https://t.co/zyZSTJLixN 3. https://t.co/mouYm7Rz3E 4. https://t.co/6QvXhBvEPp 5. https://t.co/DjmSDlzazE 6. https://t.co/AwbRdVjVYy 7. https://t.co/D1gzJbxE5u

Feb 15, 2025 · 5 likes · 10,549 followers View post →

Dr. Keith R. Brunt

@prof_brunt · X

RT @SamuelBHume: 2. Acoramidis, which stops misfolded transthyretin protein from being deposited as amyloid fibrils in the heart, in patien…

Dec 3, 2024 · 3 shares · 2,530 followers View post →

P. A-M

@PAMJ84 · X

RT @SamuelBHume: 2. Acoramidis, which stops misfolded transthyretin protein from being deposited as amyloid fibrils in the heart, in patien…

Dec 3, 2024 · 3 shares · 259 followers View post →

Samuel Hume

@DrSamuelBHume · X

Dec 3, 2024 · 49 likes · 3 shares · 28,865 followers View post →

Health Affiliate

@HudbayAffiliate · X

RT @YevgeniyBr: Exciting news from @US_FDA as we have a new drug approved for #Amyloidosis. Excited for more choices for our patients @Amy…

Nov 25, 2024 · 2 shares · 3,443 followers View post →

Melissa Lyle

@MelissaLyleMD · X

RT @YevgeniyBr: Exciting news from @US_FDA as we have a new drug approved for #Amyloidosis. Excited for more choices for our patients @Amy…

Nov 24, 2024 · 2 shares · 1,618 followers View post →

Yevgeniy Brailovsky DO MSc FACC

@YevgeniyBr · X

Nov 22, 2024 · 27 likes · 2 shares · 2,959 followers View post →

UCL Discovery

@ucl_discovery · X

Open Access UCL Research: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy https://t.co/KweUEg5dce

Jul 11, 2024 · 2,525 followers View post →

د . احمد سمان

@Ahmed43101178 · X

RT @Ed_Alania:

Jun 8, 2024 · 33 shares · 6,357 followers View post →

未来の薬

@med2024_ · X

Acoramidis トランスサイレチン安定化薬 https://t.co/v0P6dhVY0R https://t.co/JQBEO6efG1 https://t.co/yVzFC8dMtK https://t.co/pJ3blSoyOX

May 14, 2024 · 1 like · 17 followers View post →

Sociedade Portuguesa de Cardiologia

@spcardio · X

O Grupo de Estudo de Doenças do Miocárdio e Pericárdio destaca, no artigo do mês, o estudo “Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy”. Este ensaio explora o tratamento com acoramidis, um estabilizador de TTR que demonstrou resultados clínicos https://t.co/LcNXYBNdMw

Apr 23, 2024 · 1 like · 2,130 followers View post →

Novi Yanti Sari

@slumberbell · X

RT @Nikhil15: Newest #ACC Teaching Points on the efficacy of Acoramdis in ATTR Cardiac Amyloidosis (ATTribute-CM Trial) Link to paper: htt…

Apr 15, 2024 · 3 shares · 2,595 followers View post →

ACMC IM Residency

@ACMCIMRes · X

RT @Nikhil15: Newest #ACC Teaching Points on the efficacy of Acoramdis in ATTR Cardiac Amyloidosis (ATTribute-CM Trial) Link to paper: htt…

Apr 15, 2024 · 3 shares · 1,487 followers View post →

Gregory Macaluso

@gmac78 · X

RT @Nikhil15: Newest #ACC Teaching Points on the efficacy of Acoramdis in ATTR Cardiac Amyloidosis (ATTribute-CM Trial) Link to paper: htt…

Apr 15, 2024 · 3 shares · 1,714 followers View post →

Nikhil Narang, MD

@Nikhil15 · X

Newest #ACC Teaching Points on the efficacy of Acoramdis in ATTR Cardiac Amyloidosis (ATTribute-CM Trial) Link to paper: https://t.co/0M5HfCakYR Link to our clinical trial summary: https://t.co/vq5r7YmLec @amgbonaguro #ACCFIT @ACMCIMRes @cardiologyacmc https://t.co/6HaTBPyH9z https://t.co/C4tg7Uc8jD

Apr 15, 2024 · 15 likes · 3 shares · 3,054 followers View post →

Angela Lopez

@angelalopsainz · X

RT @MondaEmanuele: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy @NEJM https://t.co/tC4VSSQ5L3 https://t.co/…

Feb 20, 2024 · 3 shares · 347 followers View post →

Soraya Kakhi

@KakhiSoraya · X

RT @MondaEmanuele: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy @NEJM https://t.co/tC4VSSQ5L3 https://t.co/…

Feb 19, 2024 · 3 shares · 81 followers View post →

Emanuele Monda

@MondaEmanuele · X

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy @NEJM https://t.co/tC4VSSQ5L3 https://t.co/Kfh5XhD5pt

Feb 19, 2024 · 11 likes · 3 shares · 9,141 followers View post →

Nelson murillo

@nemurillob · X

RT @Ed_Alania:

Jan 26, 2024 · 33 shares · 247 followers View post →

Dra. Isabel Carvajal.

@estelais · X

RT @accpcardprn: Does tafamidis have some competition in ATTR cardiomyopathy management?

Jan 26, 2024 · 2 shares · 5,601 followers View post →

ACCP Cardiology PRN

@accpcardprn · X

Does tafamidis have some competition in ATTR cardiomyopathy management?

Jan 24, 2024 · 16 likes · 2 shares · 9,296 followers View post →

Michael Buratovich

@MichaelBuratovi · X

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy | PracticeUpdate https://t.co/CAGWno2b35

Jan 21, 2024 · 1,163 followers View post →

Ritu Thamman MD

@iamritu · X

RT @GiuseppeGalati_:

Jan 20, 2024 · 6 shares · 31,669 followers View post →

Andrew J Sauer MD

@AndrewJSauer · X

RT @GiuseppeGalati_:

Jan 20, 2024 · 6 shares · 19,277 followers View post →

Kamala Tamirisa MD

@KTamirisaMD · X

RT @GiuseppeGalati_:

Jan 20, 2024 · 6 shares · 9,435 followers View post →

Mamas A. Mamas

@mmamas1973 · X

RT @GiuseppeGalati_:

Jan 20, 2024 · 6 shares · 79,838 followers View post →

Giuseppe Galati

@GiuseppeGalati_ · X

Jan 20, 2024 · 17 likes · 6 shares · 10,459 followers View post →

Mattia Galli

@MattiaGalli10 · X

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy | NEJM https://t.co/d2rioPsLbT

Jan 17, 2024 · 3,189 followers View post →

Victor H Jimenez-Zepeda

@vhugo8762 · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 620 followers View post →

Joshua Bomsztyk

@JBomsztyk · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 165 followers View post →

PubMed Trending

@PubTrend · X

Trending on PubMed: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. https://t.co/3tIaqmtU5Q

Jan 17, 2024 · 5,158 followers View post →

Heet Manvar

@ManvarHeet · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 583 followers View post →

Manuel Méndez

@mendez_bailon · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 7,784 followers View post →

Jan Verwerft

@VerwerftJan · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 4,225 followers View post →

Dr. Sou

@SwissHeartDoc · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 883 followers View post →

Marcia S Newman

@marciasgreen · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 4,936 followers View post →

George Kolostoumpis

@gkolost · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 2,088 followers View post →

Erion K. Musabelliu, MD

@MusabelliuEK · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 771 followers View post →

Dr. Shashank Joshi

@AskDrShashank · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 32,513 followers View post →

カミーユ=りく

@1978rikut · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 1,273 followers View post →

mashael aljead

@PhMaljead · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 3,411 followers View post →

Maria

@paton_maria · X

RT @NEJM: ATTRibute-CM trial: In patients with transthyretin amyloid cardiomyopathy, the receipt of acoramidis resulted in a significantly…

Jan 17, 2024 · 30 shares · 1,556 followers View post →

NEJM

@NEJM · X

Jan 17, 2024 · 75 likes · 30 shares · 935,671 followers View post →

Gurbakhash Kaur

@GKaurMD · X

RT @NEJM: In patients with transthyretin amyloid cardiomyopathy, the TTR stabilizer acoramidis resulted in a better primary hierarchical ou…

Jan 16, 2024 · 51 shares · 1,283 followers View post →

Igor Morr

@igormorr · X

RT @Ed_Alania:

Jan 15, 2024 · 33 shares · 3,941 followers View post →

Dr Ramdas Pananthattil

@PananthattilR · X

RT @NEJM: Original Article: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM trial) https://t.co/0HO…

Jan 14, 2024 · 4 shares · 795 followers View post →

Paul Kim

@paulkimbx · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 13, 2024 · 11 shares · 56 followers View post →

Martin Grübler

@GrublerMartin · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 13, 2024 · 11 shares · 70 followers View post →

Dr. Osmar Perez S.

@osmarperse · X

RT @Ed_Alania:

Jan 13, 2024 · 33 shares · 2,457 followers View post →

Jamael Hoosain

@TheRealJamael · X

RT @Ed_Alania:

Jan 13, 2024 · 33 shares · 527 followers View post →

Jeapvz

@jeapvz · X

RT @NEJM: Original Article: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM trial) https://t.co/0HO…

Jan 13, 2024 · 4 shares · 54 followers View post →

Ash Paul

@pash22 · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 12, 2024 · 11 shares · 32,266 followers View post →

ONCO BRUNO

@brunolarvol · X

RT @NEJM: Original Article: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM trial) https://t.co/0HO…

Jan 12, 2024 · 4 shares · 7,256 followers View post →

NEJM

@NEJM · X

Original Article: Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM trial) https://t.co/0HOZBB9JYz #Cardiology https://t.co/OKp8ZIfxtZ

Jan 12, 2024 · 12 likes · 4 shares · 935,671 followers View post →

@MTome

@DrMaiteTome · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 12, 2024 · 28 shares · 870 followers View post →

Jeremy S. Pollock

@bmorecardiology · X

#clinicalcardiology "Win Ratios" are tough.. but this looks like we will have another drug in our armamentarium for TTR-Amyloid! Assuming we will never have a head to head trial (Tafamadis vs. Acoramids)? @NEJM https://t.co/M6mf0ETD8e https://t.co/e9dJ3g5JDL

Jan 12, 2024 · 6 likes · 1 share · 1,617 followers View post →

Dr.Félix09Rodríguez

@PhellixR · X

RT @Ed_Alania:

Jan 12, 2024 · 33 shares · 1,354 followers View post →

@MTome

@DrMaiteTome · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 12, 2024 · 11 shares · 870 followers View post →

Ravi J. Shah

@theravishah · X

RT @RyanTedfordMD: A huge congratulations to the investigators & my @MUSChealth colleague #DanJudge for his leadership of this study! @MUS…

Jan 12, 2024 · 12 shares · 642 followers View post →

Daniel

@ikeror112 · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 12, 2024 · 11 shares · 55 followers View post →

Giuseppe Biondi-Zoccai

@gbiondizoccai · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 12, 2024 · 11 shares · 12,126 followers View post →

Mariano Trevisan

@MTrevisan72 · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 12, 2024 · 11 shares · 97 followers View post →

Pauline MacLean

@pyjamaulove · X

RT @BU_Amyloidosis: Exciting news: Acoramidis triumphs in treating ATTR amyloidosis. It brings hope to those affected. Together, we are mak…

Jan 12, 2024 · 1 share · 225 followers View post →

marcbadibake

@marcbadibake · X

RT @Ed_Alania:

Jan 12, 2024 · 33 shares · 61 followers View post →

CardioInfo

@Cardioinfo_it · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 12, 2024 · 11 shares · 9,217 followers View post →

Raffaele Rasoini

@RasoiniR · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 12, 2024 · 11 shares · 424 followers View post →

Ahmed Bennis MD

@drbennisahmed · X

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy acoramidis resulted in a significantly better four-step primary hierarchical outcome https://t.co/Kaeq12oFX2

Jan 12, 2024 · 2 likes · 2,654 followers View post →

Bruno A. Costa, MD

@mdbrunocosta · X

RT @SumeetMitter: ATTRibute-CM now out in NEJM. Was an honor to be a site PI @MountSinaiHeart early in my career. Excited to enhance acce…

Jan 12, 2024 · 3 shares · 1,252 followers View post →

Syed Shahrul Naz

@drshahrul80 · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 6,929 followers View post →

Zuilma Vásquez

@VazyurVasquez · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 4,437 followers View post →

Stella M Macin

@StellaMMacin · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 549 followers View post →

Sanjay Ganapathi

@gesjay · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 11, 2024 · 11 shares · 72 followers View post →

Ahmad Masri

@MasriAhmadMD · X

RT @chriskairis1: Transthyretin amyloid cardiomyopathy. Finally TTR stabilizer is the only evidence-based therapy, which have been shown t…

Jan 11, 2024 · 1 share · 8,931 followers View post →

Tadeusz Osadnik

@TadeuszOsadnik · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 187 followers View post →

MACottingham

@MACottingham · X

@kalashnikity @TDBSubstack @BaffledDoctors @CumberpatchM @Evermoredetroit @RealGeorgeWebb1 @CoyoteSanctuary @kmidjr68 @julie74439076 @LaserFocus2000 @amy_mcdavis @hippydippygirl @53v3n0fn1n3 @SaltyDi @w_s_gosset @HousatonicLive @RWMaloneMD Maybe some movement on the de-Fibril-lation front, at least for Transthyretin amyloidosis (ATTR-CM) https://t.co/tJ8vxHrDj5 https://t.co/ygcGcxIWjS

Jan 11, 2024 · 2 likes · 910 followers View post →

Tomás Ripoll Vera MD,PhD,FESC

@tripoll · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 2,096 followers View post →

Gregory Macaluso

@gmac78 · X

RT @RyanTedfordMD: A huge congratulations to the investigators & my @MUSChealth colleague #DanJudge for his leadership of this study! @MUS…

Jan 11, 2024 · 12 shares · 1,714 followers View post →

MUSC Amyloidosis Center

@Amyloid_MUSC · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 375 followers View post →

MUSC Amyloidosis Center

@Amyloid_MUSC · X

RT @Drjhoffmanmiami: Proud to be a part of this study @SylvesterCancer - we need some competition in the TTR stabilizer space… more options…

Jan 11, 2024 · 6 shares · 375 followers View post →

BU Amyloidosis Center

@BU_Amyloidosis · X

Exciting news: Acoramidis triumphs in treating ATTR amyloidosis. It brings hope to those affected. Together, we are making a positive impact on lives. #breakthrough #amyloidosis #innovation https://t.co/ODUTRWeN61

Jan 11, 2024 · 20 likes · 1 share · 2,491 followers View post →

VCU Health Hume-Lee Transplant Center

@VCUTransplant · X

RT @KeyurBShahRIC: Very excited to have been part of this effort to expand treatment options for cardiac amyloidosis @VCUHealth @VCUHealthH…

Jan 11, 2024 · 4 shares · 545 followers View post →

diego romero cawen

@chinorigin · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 267 followers View post →

Abdallah Al-Mohammad

@AAlMohammad87 · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 926 followers View post →

john morley

@drjohnmorley · X

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy | NEJM https://t.co/qeppypOw3f

Jan 11, 2024 · 8,322 followers View post →

INTERNAL MEDICINE

@medicinterna · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 2,458 followers View post →

Ahmed Amin

@amincardio · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 352 followers View post →

JM Larrañaga

@xenux88 · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 633 followers View post →

Bayar Jaff

@JaffBayar · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 604 followers View post →

Luis Ruiz Guerrero

@LRGuerr · X

RT @drjohnm: Difficult to analyze ATTRibute-CM https://t.co/6PShLjoHDW Multiple changing endpoints. Hmm. Win-ratio is fine, but why not…

Jan 11, 2024 · 11 shares · 216 followers View post →

Gabriel Valle Matute

@mdgabovalle · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 434 followers View post →

Echocardiography

@echocardiac · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 31,909 followers View post →

Maria Hazel Cohan, DNP, AGACNP-BC, AACC

@mcvhaze · X

RT @KeyurBShahRIC: Very excited to have been part of this effort to expand treatment options for cardiac amyloidosis @VCUHealth @VCUHealthH…

Jan 11, 2024 · 4 shares · 134 followers View post →

Michael Chetrit

@ChetritMichael · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 1,094 followers View post →

Daniel Lorenzatti, MD.

@danilorenzatti · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 3,384 followers View post →

Unlikely Buddha

@Unlikely_Buddha · X

https://t.co/qRk16KK399

Jan 11, 2024 · 1,210 followers View post →

Văn Anh

@anhn67051 · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 45 followers View post →

Angela Lopez

@angelalopsainz · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 347 followers View post →

MUSC Cardiology Fellowship Programs

@MUSCCardFellows · X

Congratulations to our PD #DanJudge on his incredible work as the international co-PI for this study!

Jan 11, 2024 · 5 likes · 1,522 followers View post →

Jerry Valenzuela

@JeraValenzuela · X

RT @Ed_Alania: https://t.co/iSHX7pgKf3

Jan 11, 2024 · 2 shares · 166 followers View post →

Syed Saad Mahmood, MD

@SaadMahmoodMD · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 1,105 followers View post →

Sintayehu Abebe

@sinta_gf · X

RT @ZHeart11768530: Efficacy & Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy @NEJM In pts with transthyretin amyloid CMP, TT…

Jan 11, 2024 · 2 shares · 451 followers View post →

Sean M Riley

@SeanandGinger · X

RT @KeyurBShahRIC: Very excited to have been part of this effort to expand treatment options for cardiac amyloidosis @VCUHealth @VCUHealthH…

Jan 11, 2024 · 4 shares View post →

Dr Celestino Gutiérrez González MD

@CelestinoGutirr · X

RT @Drjhoffmanmiami: Proud to be a part of this study @SylvesterCancer - we need some competition in the TTR stabilizer space… more options…

Jan 11, 2024 · 6 shares · 11,287 followers View post →

Emer Joyce

@heartofthemater · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 1,948 followers View post →

Sylvester Comprehensive Cancer Center

@SylvesterCancer · X

RT @Drjhoffmanmiami: Proud to be a part of this study @SylvesterCancer - we need some competition in the TTR stabilizer space… more options…

Jan 11, 2024 · 6 shares · 8,897 followers View post →

Miguel Fandiño

@MiguelFL03 · X

RT @ZHeart11768530: Efficacy & Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy @NEJM In pts with transthyretin amyloid CMP, TT…

Jan 11, 2024 · 2 shares · 1 followers View post →

The Heart

@ZHeart11768530 · X

Efficacy & Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy @NEJM In pts with transthyretin amyloid CMP, TTR stabilizer acoramidis resulted in a better primary hierarchical outcome (including mortality, morbidity, and function) than placebo: https://t.co/VwIbKxawJD https://t.co/ObsM4iHR3O

Jan 11, 2024 · 8 likes · 2 shares · 32,840 followers View post →

Regina Kiefer

@KieferRegina · X

RT @RyanTedfordMD: A huge congratulations to the investigators & my @MUSChealth colleague #DanJudge for his leadership of this study! @MUS…

Jan 11, 2024 · 12 shares · 238 followers View post →

Niccolo' Maurizi

@MauriziNiccolo · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 290 followers View post →

Andrew J Sauer MD

@AndrewJSauer · X

RT @SumeetMitter: ATTRibute-CM now out in NEJM. Was an honor to be a site PI @MountSinaiHeart early in my career. Excited to enhance acce…

Jan 11, 2024 · 3 shares · 19,277 followers View post →

Roxana Campisi, MD, MTSAC, MASNC

@roxanacampisi · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 605 followers View post →

Amyloidosis Speakers Bureau

@Amyloidosis_ASB · X

RT @KeyurBShahRIC: Very excited to have been part of this effort to expand treatment options for cardiac amyloidosis @VCUHealth @VCUHealthH…

Jan 11, 2024 · 4 shares · 727 followers View post →

Amyloidosis Speakers Bureau

@Amyloidosis_ASB · X

RT @Drjhoffmanmiami: Proud to be a part of this study @SylvesterCancer - we need some competition in the TTR stabilizer space… more options…

Jan 11, 2024 · 6 shares · 727 followers View post →

Hide Yaku, MD, PhD, FHFSA

@JP_HFpEF · X

https://t.co/jaM7tDbdDe

Jan 11, 2024 · 2,050 followers View post →

Milton Larrondo

@miltonlarrondo · X

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy | NEJM https://t.co/zJSq1KjxTO

Jan 11, 2024 · 477 followers View post →

John Mandrola, MD

@drjohnm · X

Jan 11, 2024 · 56 likes · 11 shares · 68,470 followers View post →

Ivan Mendoza

@mencardio · X

RT @Ed_Alania: https://t.co/iSHX7pgKf3

Jan 11, 2024 · 2 shares · 7,259 followers View post →

Ivan Mendoza

@mencardio · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 7,259 followers View post →

Carlo Fumagalli

@CarloFumagalli1 · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 257 followers View post →

Juan Pablo Costabel MD

@jpcostabel · X

https://t.co/tQL9I9PiYO

Jan 11, 2024 · 1 like · 13,473 followers View post →

Dr. Tayyeb Muhammad

@TayyebM · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 122 followers View post →

Jeny Torres Gonzales

@JenyTorresg · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 72 followers View post →

Jose J Carvajal

@cardioactual16 · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 391 followers View post →

David de las Cuevas

@DaviddlCuevas · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 1,399 followers View post →

TaxiBiotech

@TaxiBiotech · X

Datos positivos $BBIO resultados de Fase3 en NEJM. Acormidis frente a placebo mejoras: muertes, cambios en NT-proBNP, transtiretina. https://t.co/SGdhN3VWU1

Jan 11, 2024 · 429 followers View post →

TaxiBiotech

@TaxiBiotech · X

$BBIO positive Phase3 results published in NEJM. Acoramidis better than placebo highlihts: death, change in NT-proBNP, serum transthyretin. https://t.co/SGdhN3VWU1

Jan 11, 2024 · 429 followers View post →

Federico Marchini

@Feff93 · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 572 followers View post →

Chris Kairis

@chriskairis1 · X

Transthyretin amyloid cardiomyopathy. Finally TTR stabilizer is the only evidence-based therapy, which have been shown to be efficacious in clinical practice without severe adverse events. @MasriAhmadMD @Amyloidosis_ARC @amyloid_papers @ISA_Amyloidosis https://t.co/cSvFNggZjo

Jan 11, 2024 · 4 likes · 1 share · 423 followers View post →

Alessia Argiró

@AlessiaArgiro · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 742 followers View post →

Giorgia Panichella

@PanichellaG · X

RT @MasriAhmadMD: ATTRibute-CM paper is out in @NEJM Acoramidis vs placebo in #ATTR cardiomyopathy https://t.co/ikvFC9NK0w #CatdioTwitt…

Jan 11, 2024 · 28 shares · 452 followers View post →

Dr. Sou

@SwissHeartDoc · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 883 followers View post →

Cappelli Francesco

@Cappellifrance2 · X

RT @Ed_Alania:

Jan 11, 2024 · 33 shares · 541 followers View post →

Edgardo Alania

@Ed_Alania · X

Jan 11, 2024 · 84 likes · 33 shares · 10,230 followers View post →

Ben Diamond, MD

@BenDiamondMD · X

RT @Drjhoffmanmiami: Proud to be a part of this study @SylvesterCancer - we need some competition in the TTR stabilizer space… more options…

Jan 10, 2024 · 6 shares · 808 followers View post →

hinomura

@biotechinomura · X

$BBIO Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy @NEJM https://t.co/Y9gPQZ47s4

Jan 10, 2024 · 7 likes · 95 followers View post →

Gurbakhash Kaur

@GKaurMD · X

RT @Drjhoffmanmiami: Proud to be a part of this study @SylvesterCancer - we need some competition in the TTR stabilizer space… more options…

Jan 10, 2024 · 6 shares · 1,283 followers View post →

James Hoffman

@Drjhoffmanmiami · X

Jan 10, 2024 · 30 likes · 6 shares · 3,524 followers View post →

AnesthesiaHQ

@anesthesiahq · X

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy | NEJM https://t.co/ZUzXrvQMky

Jan 10, 2024 · 14,279 followers View post →

hinomura

@biotechinomura · X

$BBIO Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy Results of the ATTRibute-CM Trial @escardio Slides: https://t.co/QLJ93HIXjQ https://t.co/849WtPAMFn

Aug 27, 2023 · 6 likes · 95 followers View post →

Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy

Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy